Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Fumio Imamura, MD, PhD"'
Autor:
Takako Inoue, MD, Takahisa Kawamura, MD, PhD, Kei Kunimasa, MD, PhD, Motohiro Tamiya, MD, Hanako Kuhara, MD, PhD, Kazumi Nishino, MD, PhD, Satomi Odani, MPH, Fumio Imamura, MD, PhD, Toru Kumagai, MD, PhD, Kotaro Miyake, MD, PhD, Mihai Dorin Vartolomei.
Publikováno v:
Medicine, Vol 101, Iss 17, p e29076 (2022)
Abstract. Virtual automatic bronchoscopic navigation (VBN) systems to determine the route to peripheral pulmonary lesions (PPLs) in lung cancer can improve diagnostic biopsy yields. However, compared with VBN, drawing manual routes using computed tom
Externí odkaz:
https://doaj.org/article/22a0acdbdab04d0e97a5679d30201c8a
Autor:
Makoto Nishio, MD, PhD, Kazuto Nishio, MD, PhD, Martin Reck, MD, PhD, Edward B. Garon, MD, Fumio Imamura, MD, PhD, Tomoya Kawaguchi, PhD, Hiroyuki Yamaguchi, MD, PhD, Satoshi Ikeda, MD, PhD, Katsuya Hirano, MD, Carla Visseren-Grul, MD, Matteo Ceccarelli, PharmD, MS, Sameera R. Wijayawardana, PhD, Annamaria Zimmermann, MS, Tomoko Matsui, Sotaro Enatsu, MD, PhD, Kazuhiko Nakagawa, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 4, Pp 100303- (2022)
Introduction: Ramucirumab (RAM) plus erlotinib was found to have superior progression-free survival (PFS) versus placebo plus erlotinib in untreated EGFR-mutated metastatic NSCLC in the global phase 3 RELAY study. RELAY+ was an open-label, two-period
Externí odkaz:
https://doaj.org/article/2c15ffbd66fc4dc2bedf92f859b0dd3f
Autor:
Kei Kunimasa, MD, PhD, Risa Kamada, MD, Toru Oka, MD, PhD, Makiko Oboshi, MD, PhD, Madoka Kimura, MD, Takako Inoue, MD, Motohiro Tamiya, MD, Tatsuya Nishikawa, MD, PhD, Taku Yasui, MD, PhD, Wataru Shioyama, MD, PhD, Kazumi Nishino, MD, PhD, Fumio Imamura, MD, PhD, Toru Kumagai, MD, PhD, Masashi Fujita, MD, PhD
Publikováno v:
JACC. CardioOncology, Vol 2, Iss 1, Pp 1-10 (2020)
Objectives: The purpose of this study was to assess osimertinib-associated cardiac adverse events (AEs) in a real-world setting, using a retrospective single-center cohort study in Japan. Background: Cases of osimertinib-associated cardiac AEs have b
Externí odkaz:
https://doaj.org/article/cd084dc47bf644bfa229ea9866542e66